Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.

Article  PubMed  Google Scholar 

Jiang D, Li X, Wang H, et al. The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma. BMC Cancer. 2015;15:377. https://doi.org/10.1186/s12885-015-1393-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu ZD, Li JY, Li M, et al. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol. 2005;100(8):1835–43. https://doi.org/10.1111/j.1572-0241.2005.50018.x. Erratum in: Am J Gastroenterol. 2006 Sep;101(9):2171.

Article  CAS  PubMed  Google Scholar 

Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91–5. https://doi.org/10.1038/nature13176.

Article  CAS  PubMed  Google Scholar 

Brenner B, Purim O, Gordon N, et al. The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial. Radiother Oncol. 2019;134:74–80. https://doi.org/10.1016/j.radonc.2019.01.013.

Article  CAS  PubMed  Google Scholar 

Sakaguchi S, Vignali DA, Rudensky AY, et al. The plasticity and stability of regulatory T cells. Nat Rev Immunol. 2013;13(6):461–7. https://doi.org/10.1038/nri3464.

Article  CAS  PubMed  Google Scholar 

Luo Q, Zhang S, Wei H, et al. Roles of Foxp3 in the occurrence and development of cervical cancer. Int J Clin Exp Pathol. 2015;8(8):8717–30.

PubMed  PubMed Central  Google Scholar 

Zhu J, Li Z, Chen J, et al. A comprehensive bioinformatics analysis of FOXP3 in nonsmall cell lung cancer. Medicine. 2022;101(50):e32102. https://doi.org/10.1097/MD.0000000000032102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X, Feng Z, Wang Y, et al. Expression of Foxp3 and its prognostic significance in colorectal cancer. Int J Immunopathol Pharmacol. 2017;30(2):201–6. https://doi.org/10.1177/0394632017710415.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang B, Dou Y, Xu X, et al. Endogenous FOXP3 inhibits cell proliferation, migration and invasion in glioma cells. Int J Clin Exp Med. 2015;8(2):1792–802.

PubMed  PubMed Central  Google Scholar 

Wu L, Yi B, Wei S, et al. Loss of FOXP3 and TSC1 accelerates prostate cancer progression through synergistic transcriptional and posttranslational regulation of c‑MYC. Cancer Res. 2019;79(7):1413–25. https://doi.org/10.1158/0008-5472.CAN-18-2049.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu C, Han J, Li X, et al. FOXP3 inhibits the metastasis of breast cancer by downregulating the expression of MTA1. Front Oncol. 2021;11:656190. https://doi.org/10.3389/fonc.2021.656190.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang S, Zhang Y, Wang Y, et al. Amphiregulin confers regulatory T cell suppressive function and tumor invasion via the EGFR/GSK-3β/Foxp3 axis. J Biol Chem. 2016;291(40):21085–95. https://doi.org/10.1074/jbc.M116.717892.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330–6. https://doi.org/10.1038/ni904.

Article  CAS  PubMed  Google Scholar 

Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490–500. https://doi.org/10.1038/nri2785.

Article  CAS  PubMed  Google Scholar 

Xue L, Lu HQ, He J, et al. Expression of FOXP3 in esophageal squamous cell carcinoma relating to the clinical data. Dis Esophagus. 2010;23(4):340–6. https://doi.org/10.1111/j.1442-2050.2009.01013.x.

Article  CAS  PubMed  Google Scholar 

Wang G, Liu G, Liu Y, et al. FOXP3 expression in esophageal cancer cells is associated with poor prognosis in esophageal cancer. Hepatogastroenterology. 2012;59(119):2186–91. https://doi.org/10.5754/hge11961.

Article  PubMed  Google Scholar 

Li C, Yang W, Gai X, Zhang Y, et al. Foxp3 overexpression decreases sensitivity to chemotherapy in mouse Lewis lung cancer cells. Mol Med Rep. 2012;6(5):977–82. https://doi.org/10.3892/mmr.2012.1066.

Article  CAS  PubMed  Google Scholar 

Wang G, Sun Y, Ji C, et al. Correlation between the CD4+CD25high regulatory T cells and the outcome of chemotherapy in advanced esophageal carcinoma. Hepatogastroenterology. 2013;60(124):704–8. https://doi.org/10.5754/hge12953.

Article  CAS  PubMed  Google Scholar 

Xu T, Duan Q, Wang G, et al. CD4 + CD25high regulatory T cell numbers and FOXP3 mRNA expression in patients with advanced esophageal cancer before and after chemotherapy. Cell Biochem Biophys. 2011;61(2):389–92. https://doi.org/10.1007/s12013-011-9197-1.

Article  CAS  PubMed  Google Scholar 

Li C, Sun L, Jiang R, et al. Downregulation of FOXP3 inhibits cell proliferation and enhances chemosensitivity to cisplatin in human lung adenocarcinoma. Pathol Res Pract. 2017;213(10):1251–6. https://doi.org/10.1016/j.prp.2017.09.004.

Article  CAS  PubMed  Google Scholar 

Tanaka A, Nishikawa H, Noguchi S, et al. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med. 2020;217(2):e20191009. https://doi.org/10.1084/jem.20191009.

Article  CAS  PubMed  Google Scholar 

Isomoto K, Haratani K, Hayashi H, et al. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res. 2020;26(8):2037–46. https://doi.org/10.1158/1078-0432.CCR-19-2027.

Article  CAS  PubMed  Google Scholar 

Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22(6):883–92. https://doi.org/10.1016/S1470-2045(21)00136-4.

Article  CAS  PubMed  Google Scholar 

Chung CH, Li J, Steuer CE, et al. Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2022;28(11):2329–38. https://doi.org/10.1158/1078-0432.CCR-21-3849.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito M, Komai K, Mise-Omata S, et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature. 2019;565(7738):246–50. https://doi.org/10.1038/s41586-018-0824-5.

Article  CAS  PubMed  Google Scholar 

Jiang R, Tang J, Chen Y, et al. The long noncoding RNA lnc-EGFR stimulates T‑regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun. 2017;8:15129. https://doi.org/10.1038/ncomms15129.

Article  CAS  PubMed  PubMed Central  Google Scholar